Rise and shine. Another busy day is on the way. As always, a slew of phone calls and meetings beckon. We trust you can relate. So please join us as we indulge in our daily ritual of brewing a delicious cup of stimulation, which appears to have fortifying properties. Of course, no morning greeting would be complete without noting that we have included a few items of interest for you. Hope your day goes well and do stay in touch...
Merck Lowers Istenress Price For State AIDS Programs (Bloomberg News)
Pharma Shifts Focus To Pleasing Payers For Reimbursement (Reuters)
EU Squeezes Supplies Of Drugs For US Executions (Reuters)
Lilly And Immunogen To Collaborate On Cancer Drugs (Dow Jones)
Merck Told To Drop Coppertone Advertising Claim (Cosmetic Design)
Lundbeck Sees European Approval For Alcohol Drug (Reuters)
Merck Axes Alzheimer's Deal With Acumen (GenengNews)
Massachusetts Recovers $24M From Merck For Medicaid Fraud (Boston Globe)
AstraZeneca Strikes Two New Deals After R&D Setbacks (Reuters)
Serbia Details Former Pharma Director Over Swine Flu Vaccine Purchases (B92)
Marsh Wins $19.5 Million Judgement Against Roche (Indianapolis Business Journal)
Takeda Buys Intellikine For Up To $310M (RTT News)
Feds Want Share Of Settlement From Medicaid Overpayments (WTVA)
Importer Of Fake Impotence Pill Must Pay Lilly And Pfizer (Indianapolis Star)
EDITOR'S NOTE: Please check this post for updates throughout the morning
tea kettle thx to mirahartford on flickr